Cadrenal Therapeutics (CVKD) Competitors $14.18 -0.01 (-0.07%) Closing price 10/3/2025 03:58 PM EasternExtended Trading$14.30 +0.12 (+0.81%) As of 10/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVKD vs. ANIX, ZNTL, STTK, KLRS, ANRO, VTGN, ORMP, HLVX, SRZN, and MEIPShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Anixa Biosciences (ANIX), Zentalis Pharmaceuticals (ZNTL), Shattuck Labs (STTK), Kalaris Therapeutics (KLRS), Alto Neuroscience (ANRO), VistaGen Therapeutics (VTGN), Oramed Pharmaceuticals (ORMP), HilleVax (HLVX), Surrozen (SRZN), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Its Competitors Anixa Biosciences Zentalis Pharmaceuticals Shattuck Labs Kalaris Therapeutics Alto Neuroscience VistaGen Therapeutics Oramed Pharmaceuticals HilleVax Surrozen MEI Pharma Anixa Biosciences (NASDAQ:ANIX) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings. Which has preferable valuation & earnings, ANIX or CVKD? Cadrenal Therapeutics has lower revenue, but higher earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnixa Biosciences$210K512.61-$12.55M-$0.35-9.34Cadrenal TherapeuticsN/AN/A-$10.65M-$8.88-1.60 Do analysts recommend ANIX or CVKD? Anixa Biosciences presently has a consensus price target of $9.00, suggesting a potential upside of 175.23%. Cadrenal Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 125.67%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Anixa Biosciences is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ANIX or CVKD more profitable? Anixa Biosciences' return on equity of -67.45% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Anixa BiosciencesN/A -67.45% -59.18% Cadrenal Therapeutics N/A -265.37%-196.38% Does the media prefer ANIX or CVKD? In the previous week, Cadrenal Therapeutics had 8 more articles in the media than Anixa Biosciences. MarketBeat recorded 8 mentions for Cadrenal Therapeutics and 0 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 0.00 beat Cadrenal Therapeutics' score of -0.14 indicating that Anixa Biosciences is being referred to more favorably in the media. Company Overall Sentiment Anixa Biosciences Neutral Cadrenal Therapeutics Neutral Do insiders and institutionals hold more shares of ANIX or CVKD? 29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 25.3% of Anixa Biosciences shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, ANIX or CVKD? Anixa Biosciences has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. SummaryAnixa Biosciences beats Cadrenal Therapeutics on 9 of the 14 factors compared between the two stocks. Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.03M$3.36B$6.14B$10.58BDividend YieldN/A2.28%5.67%4.69%P/E Ratio-1.6022.1478.0526.70Price / SalesN/A458.33605.13131.81Price / CashN/A47.8637.9061.31Price / Book3.409.9312.556.55Net Income-$10.65M-$52.80M$3.31B$277.50M7 Day Performance1.07%5.22%4.28%2.41%1 Month Performance13.35%13.01%7.85%9.30%1 Year Performance18.17%25.18%71.37%31.22% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics2.4774 of 5 stars$14.18-0.1%$32.00+125.7%+24.4%$29.03MN/A-1.604ANIXAnixa Biosciences2.6261 of 5 stars$3.36-1.6%$9.00+168.3%+3.8%$110.45M$210K-9.595ZNTLZentalis Pharmaceuticals1.4602 of 5 stars$1.53+2.3%$5.84+283.0%-49.7%$110.01M$67.43M-0.67160STTKShattuck Labs3.9843 of 5 stars$2.30+1.3%$4.00+73.9%+83.6%$109.93M$5.72M-1.90100News CoveragePositive NewsShort Interest ↓KLRSKalaris Therapeutics1.383 of 5 stars$5.84-8.0%$3.00-48.6%N/A$109.21MN/A0.00110News CoveragePositive NewsAnalyst UpgradeShort Interest ↑ANROAlto Neuroscience2.2465 of 5 stars$4.01-0.1%$9.80+144.7%-32.6%$108.46MN/A-1.68N/AAnalyst RevisionGap UpVTGNVistaGen Therapeutics1.1265 of 5 stars$3.50-1.3%N/A+23.7%$106.61M$490K-1.9540ORMPOramed Pharmaceuticals1.2314 of 5 stars$2.60-3.9%N/A+1.2%$106.40M$1.34M-7.4110Short Interest ↓HLVXHilleVax1.0969 of 5 stars$2.09flat$2.00-4.3%N/A$104.79MN/A-1.4620SRZNSurrozen1.7858 of 5 stars$12.23+4.8%$38.50+214.9%+28.1%$104.77M$10.65M-0.8580Positive NewsGap UpHigh Trading VolumeMEIPMEI Pharma0.7586 of 5 stars$3.19+14.7%N/A+16.0%$104.72MN/A-0.67100Gap UpHigh Trading Volume Related Companies and Tools Related Companies ANIX Competitors ZNTL Competitors STTK Competitors KLRS Competitors ANRO Competitors VTGN Competitors ORMP Competitors HLVX Competitors SRZN Competitors MEIP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVKD) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredIs $1M Enough to Retire Comfortably in 2025?Many people hope to retire with $1 million in savings, but how long will it really last? The answer can...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
